A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus

Summary

This is a randomized, open-label, dulaglutide-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, and immunogenicity of different doses of TG103 injection in combination with metformin in subjects with type 2 diabetes with poor glycemic control treated with metformin monotherapy.

Timeline

Start

2024-04-08

Primary completion

2026-02-03

Completion

2026-02-03

Outcome

Met primary endpoint

release “the reduction in HbA1c at Week 28 for each dose group of TG103 Injection was non-inferior to that in the dulaglutide 1.5 mg group.” irasia.com ↗

Drugs

Indications